The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet ...

Treating the brain cancer glioblastoma (GBM) demands more than conventional strategies due to a mix of factors including the cancer’s genetic complexity, invasive growth, and immune resistance. A new ...

Scientists have discovered a new immunotherapy strategy that reduces cancer recurrence in mouse experimental models. The study, published in Nature Communications, shows that a specific subtype of ...

Aggregating ‘negative’ immunotherapy trials can uncover reproducible immune perturbations that are missed in single studies, reframing lack of clinical benefit as potentially informative biologic ...

Overview of the manufacturing process of personalized neoantigen-based DC vaccines. A typical basic process of manufacturing neoantigen-based DC vaccines by using monocyte-derived dendritic cells is ...

As Head of the Clinical Advisory Board, Prof. Eggermont will guide Tidewave's clinical roadmap, trial design strategy, and translational positioning across solid tumor indications.

Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors. Safety and immunologic efficacy of personalized multiple HLA class I-restricted ...

Favorable safety profile and encouraging early efficacy signals support advancement to Phase II trial of dendritic cell vaccine for the treatment of glioblastoma. HOUSTON, June 2, 2025 /PRNewswire/ -- ...

Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't respond to this immunotherapy for reasons not yet fully understood.

To date, human anti-tumor vaccination has not delivered on its promises. Reasons for failure include tumor immune escape mechanisms, limited availability of tumor specific antigens, as well as failure ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...